File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1210/jcem.83.2.4598
- Scopus: eid_2-s2.0-0031733511
- PMID: 9467567
- WOS: WOS:000071823900037
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy
Title | A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy |
---|---|
Authors | |
Issue Date | 1998 |
Publisher | The Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org |
Citation | Journal of Clinical Endocrinology and Metabolism, 1998, v. 83 n. 2, p. 514-518 How to Cite? |
Abstract | Remission of Graves' disease (GD) during pregnancy with recrudescence after delivery is commonly observed. However, as pregnancy is associated with type 2 rather than type 1 cytokine production, a decrease in thyroid- stimulating antibody (TSAb) activity alone is unlikely to account for the remission during pregnancy. We hypothesized that a change in the antibody characteristics may occur as pregnancy advances. Fifteen women were studied in the first, second, and third trimesters of pregnancy and 4 months postpartum. TSH receptor antibodies were determined using human thyroid cell cultures, and lymphocyte subsets were measured by flow cytometry. Median TSAb (determined by cAMP release) decreased from 280% (96-3200) to 130% (range, 35-350; P < 0.05) during pregnancy, but no significant change was noted with the TSH binding inhibitory antibody (TBII; determined by RRA). Thyroid stimulation-blocking antibody (TSBAb; inhibition of TSH-stimulated cAMP release) increased from 16 ± 9% to 43 ± 16% (mean ± SD; P < 0.005). The increase in TSBAb was observed even among those patients who were in clinical remission before pregnancy. Overall, a negative correlation was observed between TSBAb activities and free T4 levels during pregnancy (r = -0.279; P < 0.05). Reciprocal changes in TSAb, TBII, and TSBAb levels were observed in the seven patients who relapsed during the postpartum period. In comparison, the healthy pregnant women (n = 14) were all negative for TSAb, TBII, and TSBAb throughout pregnancy. The absolute number oft lymphocytes, T helper cells, and natural killer cells, but not B cells, decreased significantly during pregnancy in both healthy women and GD patients. GD patients had significantly more CD5+ B cells at all stages of pregnancy compared to controls. In conclusion, a change in specificity from stimulatory to blocking antibodies was observed in GD patients during pregnancy and may contribute to the remission of GD during pregnancy. |
Persistent Identifier | http://hdl.handle.net/10722/49077 |
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 1.899 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kung, AWC | en_HK |
dc.contributor.author | Jones, BM | en_HK |
dc.date.accessioned | 2008-06-12T06:33:54Z | - |
dc.date.available | 2008-06-12T06:33:54Z | - |
dc.date.issued | 1998 | en_HK |
dc.identifier.citation | Journal of Clinical Endocrinology and Metabolism, 1998, v. 83 n. 2, p. 514-518 | en_HK |
dc.identifier.issn | 0021-972X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/49077 | - |
dc.description.abstract | Remission of Graves' disease (GD) during pregnancy with recrudescence after delivery is commonly observed. However, as pregnancy is associated with type 2 rather than type 1 cytokine production, a decrease in thyroid- stimulating antibody (TSAb) activity alone is unlikely to account for the remission during pregnancy. We hypothesized that a change in the antibody characteristics may occur as pregnancy advances. Fifteen women were studied in the first, second, and third trimesters of pregnancy and 4 months postpartum. TSH receptor antibodies were determined using human thyroid cell cultures, and lymphocyte subsets were measured by flow cytometry. Median TSAb (determined by cAMP release) decreased from 280% (96-3200) to 130% (range, 35-350; P < 0.05) during pregnancy, but no significant change was noted with the TSH binding inhibitory antibody (TBII; determined by RRA). Thyroid stimulation-blocking antibody (TSBAb; inhibition of TSH-stimulated cAMP release) increased from 16 ± 9% to 43 ± 16% (mean ± SD; P < 0.005). The increase in TSBAb was observed even among those patients who were in clinical remission before pregnancy. Overall, a negative correlation was observed between TSBAb activities and free T4 levels during pregnancy (r = -0.279; P < 0.05). Reciprocal changes in TSAb, TBII, and TSBAb levels were observed in the seven patients who relapsed during the postpartum period. In comparison, the healthy pregnant women (n = 14) were all negative for TSAb, TBII, and TSBAb throughout pregnancy. The absolute number oft lymphocytes, T helper cells, and natural killer cells, but not B cells, decreased significantly during pregnancy in both healthy women and GD patients. GD patients had significantly more CD5+ B cells at all stages of pregnancy compared to controls. In conclusion, a change in specificity from stimulatory to blocking antibodies was observed in GD patients during pregnancy and may contribute to the remission of GD during pregnancy. | en_HK |
dc.format.extent | 418 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | eng | en_HK |
dc.publisher | The Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org | en_HK |
dc.relation.ispartof | Journal of Clinical Endocrinology and Metabolism | en_HK |
dc.subject.mesh | Antibodies, Blocking - blood | en_HK |
dc.subject.mesh | Autoantibodies - blood | en_HK |
dc.subject.mesh | Graves Disease - blood - immunology | en_HK |
dc.subject.mesh | Immunoglobulins, Thyroid-Stimulating - blood - immunology | en_HK |
dc.subject.mesh | Pregnancy Complications - immunology | en_HK |
dc.title | A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Kung, AWC:awckung@hku.hk | en_HK |
dc.identifier.authority | Kung, AWC=rp00368 | en_HK |
dc.description.nature | link_to_OA_fulltext | en_HK |
dc.identifier.doi | 10.1210/jcem.83.2.4598 | en_HK |
dc.identifier.pmid | 9467567 | - |
dc.identifier.scopus | eid_2-s2.0-0031733511 | en_HK |
dc.identifier.hkuros | 34044 | - |
dc.identifier.hkuros | 41348 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0031733511&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 83 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 514 | en_HK |
dc.identifier.epage | 518 | en_HK |
dc.identifier.isi | WOS:000071823900037 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Kung, AWC=7102322339 | en_HK |
dc.identifier.scopusauthorid | Jones, BM=7404958958 | en_HK |
dc.identifier.issnl | 0021-972X | - |